Ruxolitinib: Second-Line Treatment for Bronchiolitis Obliterans
Ruxolitinib, a JAK1/2 inhibitor, is being evaluated as a second‑line therapy for bronchiolitis obliterans (BO) in patients who fail conventional steroids. A recent multicenter Phase II trial involving 48 post‑transplant recipients reported a 45% median improvement in forced expiratory volume and stabilization of disease in the majority of participants. Safety data indicated mostly mild adverse events, with anemia being the most common. The findings suggest ruxolitinib could fill a critical therapeutic gap for refractory BO.
FDA Rejects Anktiva Expansion After Mischaracterized Meeting
My colleague @adamfeuerstein is reporting today that @DrPatrick "mischaracterized the outcome of a face-to-face meeting he had with FDA officials" to broaden the use of Anktiva, the bladder cancer drug that is sold by ImmunityBio, where Soon-Shiong is chairman. Adam reports...
Takeda 'Anticipated' Medicare Negotiations for Top Seller Entyvio
Takeda’s incoming CEO Julie Kim said the company anticipated Medicare’s selection of Entyvio for upcoming coverage negotiations. Entyvio, Takeda’s top-selling inflammatory‑bowel‑disease biologic, generated roughly $2.5 billion in 2023 revenue. While the firm expects a constructive dialogue, it has not disclosed pricing...
Engineering Graphene to Block and Detect Malaria
A recent review in Advanced NanoBiomed Research maps how graphene and its derivatives could be deployed at multiple points in the malaria fight. It details synthesis routes—from mechanical exfoliation to green chemistry— and highlights three intervention zones: physical barriers on...
Electrographic Cue Reactivity Aligns with Accumbens DBS
A recent study demonstrates that electrographic cue reactivity measured in the nucleus accumbens aligns closely with clinical outcomes of deep brain stimulation (DBS) for addiction and mood disorders. Researchers recorded local field potentials while subjects were exposed to drug‑related cues...
Scalable In-Situ Fabrication of Multimodal E-Skin
Researchers led by Lim, Choi, and Han have introduced a scalable in‑situ fabrication method for multimodal electronic skin that integrates pressure, temperature, and strain sensors directly onto robotic surfaces. The process combines deposition and patterning in a single workflow, using...
Takeda Is ‘Not in Favor’ of Trump’s MFN Deals, CEO-Designate Says
Takeda’s incoming chief executive publicly stated that the company is not supportive of President Donald Trump’s proposed “most favored nation” (MFN) agreements with pharmaceutical manufacturers. The MFN framework would grant U.S. drugmakers preferential pricing and market‑access terms, a move Takeda...
MXene Hydrogel Sensor Enables Heart and Breathing Monitoring in Endurance Sports
A stretchable MXene‑based hydrogel sensor has been demonstrated to monitor heart rate and respiration continuously during intense endurance exercise. The dual‑network polymer retains over 94 % of its water content after six hours at 38 °C, stretches up to 800 % strain, and...
Reading Neurochemical Signals with Integrated Graphene-CMOS
Researchers at INL unveiled a CMOS platform that simultaneously reads 32 graphene field‑effect transistor sensors at 16 kS/s per channel, enabling real‑time, high‑resolution mapping of neurochemical signals. The integrated chip converts minute ionic currents into digital data while maintaining low power...
2025 Novel Large Molecule FDA Drug Approvals
In 2025 the FDA approved fifteen novel large‑molecule therapies, representing 33 % of all new drug approvals that year. The slate was dominated by oncology biologics, including five antibody‑drug conjugates and bispecific antibodies, while non‑cancer indications saw first‑in‑class agents for hereditary...
Strawberry Cultivars’ Anthocyanins and Anti-Inflammatory Effects
A recent study examined the anthocyanin profiles of multiple strawberry cultivars and linked higher pigment concentrations to measurable anti‑inflammatory effects in vitro and in animal models. Researchers identified three cultivars with up to 45 % more anthocyanins than standard varieties, correlating...
The Disrupted Fate of Pharmacy Startups
The House Judiciary Committee released a report alleging that CVS Health engaged in antitrust practices to suppress disruptive pharmacy startups. The findings highlight potential collusion with insurers and pharmacy benefit managers to limit market entry. Industry observers note that the...
Bead-Free CAR T Cells Via Two-Stage Microfluidics
Researchers introduced a two‑stage inertial microfluidic platform that enriches activated T‑cells without magnetic beads. The label‑free approach separates cells by size, shape and deformability, delivering higher purity and viability for CAR‑T manufacturing. Compatibility with closed‑system GMP processes lowers contamination risk...
Nanoclay-Melon Protein Coatings Extend Mushroom Shelf Life
Researchers have created an edible nanoclay‑melon protein coating that dramatically prolongs the shelf life of fresh mushrooms. Laboratory tests showed the coating extended freshness by up to seven days and cut weight loss by roughly 40% compared with untreated produce....
Pipeline Cuts for Sanofi; Breakthru Medicine Raises $60M
Sanofi announced a broad portfolio review that will cut several late‑stage drug programs, aiming to streamline its pipeline and improve cost efficiency. The cull affects multiple candidates across therapeutic areas, though specific names were not disclosed. In parallel, Breakthru Medicine...
Breakthru Medicine Raises $60M in Series A Funding
Breakthru Medicine, a Phoenix‑based oncology startup, announced a $60 million Series A round led by a board of seasoned investors including Dave Morehead, Fred Eshelman and Mark Gergen. The capital will fund expansion of its precision‑therapy platform targeting solid tumors deemed “undruggable.” Breakthru’s pipeline...
Summit Says FDA Will Decide to Approve Its Cancer Drug by November
Summit Therapeutics announced that the U.S. Food and Drug Administration has set a target date of November 2024 to render a decision on its flagship cancer immunotherapy. The drug, positioned as a next‑generation immuno‑oncology agent, has completed its pivotal Phase III...
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
Biotech is emerging from a multi‑year slump into a new cycle driven by late‑stage, asset‑centric deals, as highlighted at JPM 2026. While headline megadeals were scarce, rumors around Revolution Medicines and Abivax and announced transactions such as Eli Lilly‑Ventyx and GSK‑RAPT underscored...
Type 2 Diabetes and Liver Disease in Tanzania: Insights
A Tanzanian cohort study found that 30% of patients with type 2 diabetes exhibit metabolic dysfunction‑associated steatotic liver disease (MASLD). Obesity, high‑calorie diets and physical inactivity emerged as the strongest predictors, while hypertension and dyslipidemia frequently co‑occurred. The research highlights a...
Is Platelet-to-Neutrophil Ratio Key for Sickle Cell Care?
A recent multicenter study proposes the platelet‑to‑neutrophil ratio (PNR) as a novel biomarker for managing sickle cell disease. Researchers found that patients with elevated PNR experienced more frequent vaso‑occlusive crises and higher hospitalization rates. The ratio, derived from a routine...
Cost Analysis of Obesity Treatment in Iran
Iran’s obesity prevalence has risen to about 25%, driving a sharp increase in treatment demand and costs. Direct medical spending on obesity now exceeds 1% of the national health budget, with bariatric surgery accounting for nearly half of that outlay....
AstraZeneca Pledges $15B More in Chinese Investments for Cell Therapies, Radiopharma
AstraZeneca announced a $15 billion investment in its China operations through 2030, aimed at bolstering capabilities in cell therapies and radioconjugates. The funding will support the full drug development chain, from design to manufacturing, and expand existing production sites in Wuxi,...
Sanofi Suffers Another Sales Dip For 'Gift to Public Health' Vaccines
Sanofi reported a 2.5% decline in 2025 vaccine revenue to €2 bn, marking a continued sales dip amid rising U.S. vaccine skepticism. The drop was offset by a 31.5% surge in flu and COVID‑19 vaccine sales, driven by higher virus circulation...
Barbados Government and BioMed X Partner to Improve AI-Based Early Diabetic Kidney Disease Modeling
BioMed X, a German pharma innovation hub, has teamed up with the Barbados government and the EU’s PharmaNext programme to launch an AI‑enabled research initiative targeting early diabetic kidney disease in the island’s type‑2 diabetes population. The project will combine...
Sleep Disturbance and Mobile Phone Use: Network Links
A recent study employing network analysis links mobile phone usage patterns to sleep disturbance. The research finds that high-frequency nighttime screen time, especially blue‑light exposure, is the strongest predictor of reduced sleep duration and poorer sleep quality. Young adults and...
Roche Predicts Its Breast Cancer Pill Could Become Its Biggest-Selling Drug
Roche’s oral breast‑cancer therapy is gaining momentum after two positive late‑stage trial readouts demonstrated strong efficacy and tolerable safety. The company has submitted a U.S. FDA filing and expects a decision later this year. An additional pivotal trial will report...
Following Abivax, Formation Bio Licenses miR-124 Drug From China
Formation Bio announced a licensing agreement to acquire rights to a miR‑124‑based drug candidate from a Chinese partner, mirroring the target of French biotech Abivax’s recently successful ulcerative colitis therapy. The deal positions Formation Bio to enter the rapidly expanding...
One-Step 3D Microfluidic Chip Brings Cells Closer to Real Tissues
Researchers at the University of Macau introduced a digital microfluidic chip fabricated in a single 3D‑printing step that incorporates micro‑structured wells directly onto the electrodes. The device precisely moves droplets, captures cells, and rapidly forms viable 3D spheroids that persist...
Sanofi Says Its €15B Dealmaking Budget, R&D Spend Should Help Ease Looming Dupixent Patent Cliff
Sanofi announced a €14‑15 billion budget for mergers and acquisitions in 2026, alongside a bolstered R&D spend of roughly €7 billion. The pharmaceutical giant aims to counter the looming revenue gap from Dupixent’s patent expiration expected around 2027. Management expects the combined...
Lilly Establishes up to $2.7B Repertoire Deal in Second Immune Play of 2026
Eli Lilly has signed a strategic alliance with Repertoire Immune Medicines, providing $85 million upfront and up to $1.84 billion in milestone payments to develop T‑cell‑targeted therapies for autoimmune diseases. The collaboration will use Repertoire’s DECODE platform to pinpoint T‑cell antigen interactions, aiming...
Exercise Reduces Inflammatory TMAO Produced by the Gut Microbiome
Researchers demonstrated that regular exercise markedly reduces the gut‑derived inflammatory metabolite trimethylamine N‑oxide (TMAO) in an aging rat model, lowering plasma TMAO by roughly 40%. The reduction coincided with significant improvements in cognitive performance, with the discrimination index rising 22.6%...
Biopharma Sentiment Surges, Fueling M&A and IPO Boom
Biopharma sentiment just snapped higher $XBI BPSI index jumped 78 to 90 in Q1. That is not a grind. That is a turn. Under the hood: >Current Conditions surged 58 to 75. Pain is easing now, not someday. >12-month Expectations hit 100 for the first...
Ex‑Vaccine Court Lawyer Now Guides
This Teen Never Got His Day in Vaccine Court. His Former Lawyer Now Advises RFK on Its Overhaul. This story complicates the simple. https://t.co/RSrad8WOnh
Bone Targeted Delivery of Mitochondria Wrapped in Artificial Cell Membranes
Researchers have engineered artificial cell microspheres (Fmito@ACs) that encapsulate healthy mitochondria from fetal mouse mesenchymal stem cells, shielding them from degradation in circulation. By applying an external magnetic field, these microspheres can be directed to bone fracture sites, where they...
Leaked Data Reveals Mechanisms of JNJ and MRK ADCs
With a tipoff from a friend, and some info that probably shouldn't have been posted in a trial registry, the mechanisms of ADCs JNJ-95437446 $JNJ & SKB571/ MK-2750 $MRK have been revealed. Quite amazing given the recent $GMAB news. Via...
SNY Drops Alphamedix, Opening Window for CATX
Looks like $SNY discontinued Alphamedix/ SAR447873, licensed in Sep 2024 from Radiomedix & Orano Med, h/t B Riley. @ByMadeleineA covered it at #Esmo25 and flagged dysphagia & renal tox. https://t.co/6L2O0c5cOA Good news for $CATX?
ENA Respiratory Begins Dosing in Phase 2 Study of INNA‑051 Nasal Spray
ENA Respiratory has initiated dosing in a Phase 2 clinical trial of its intranasal antiviral, INNA‑051. The study evaluates the spray’s ability to curb viral replication in the upper respiratory tract of adults presenting mild respiratory symptoms. Approximately 200 participants will...
Anti‑vax Groups Target State Vaccine Mandates After CDC List
#CDC sets the list of vaccinations recommended for all kids. But decisions about which inoculations kids require for school entry are made at the state level. Anti-vax forces are shifting their focus there @danielpayne.bsky.social & @isabellacueto.bsky.social report. https://t.co/9VPajcWzdI
Vaccines Strain Pediatric Practices, Not Boost Doctor Profits
People who oppose #vaccines often claim that doctors push them because they're paid to by Pharma or that vaccine administration is a big revenue source for doctors. The reality: Delivering vaccine puts an economic strain on many pediatric practices. https://t.co/cyJj1M2SPB
Otsuka Preps for July Decision on Centanafadine for ADHD
The FDA has placed Otsuka Pharma’s centanafidine under priority review, with a decision expected by July 24. The drug is the first norepinephrine‑dopamine‑serotonin reuptake inhibitor (NDSRI) aimed at children, adolescents, and adults with ADHD, and is backed by four phase 3 trials...
Understanding Login vs Interactive Shells in Bioinformatics
Bioinformatics is more about biology and code. It's shells and sessions, exports and environments. Ever been confused by “login shell” vs “interactive shell”? This thread is for you. 🧵 https://t.co/DfB8BEztiD
TP53 Mutations Linked to Poor Prognosis in DLBCL
A multi‑center analysis published this week links TP53 mutations to markedly poorer outcomes in diffuse large B‑cell lymphoma (DLBCL). The study, encompassing 1,200 patients treated with R‑CHOP, found TP53 alterations in roughly 20% of cases and associated them with a...
Two Days of Oatmeal Reduce Cholesterol Level
A University of Bonn randomized trial found that a two‑day, calorie‑restricted oatmeal diet lowered LDL cholesterol by about 10% in participants with metabolic syndrome. The intensive oat regimen also produced an average two‑kilogram weight loss and modest blood‑pressure reductions. Gut‑microbiome...
Evolving Views on Hearing Aids and Abandonment
A recent industry study reveals that hearing‑aid abandonment rates have fallen to 15% in the U.S., down from 30% a decade ago, driven by improved device comfort, AI‑powered personalization, and direct‑to‑consumer sales channels. The research highlights that younger adults (35‑54)...
NIR‐Triggered 3D‐Bioprinted Hydrogels for Antibacterial Skin Regeneration
Researchers have developed a near‑infrared (NIR) triggered hydrogel bio‑ink that incorporates up‑conversion nanoparticles (UCNPs) with acrylic acid‑N‑vinyl‑2‑pyrrolidone and carboxymethyl cellulose. The NIR exposure induces rapid hydrogen‑bonding condensation, enabling in‑situ 3D printing of wound‑filling scaffolds. The printed hydrogel generates reactive oxygen...
Bioinspired Ultratough and Rapidly Responsive Hydrogels Empower Silent Communication
Researchers have engineered a starch‑based hydrogel by covalently grafting protocatechuic acid, creating a bioinspired material that is both ultratough and rapidly piezoresistive. The hydrogel’s dynamic hydrogen bonds and π‑π interactions eliminate the typical brittleness‑hysteresis trade‑off, enabling reliable strain‑dependent resistance. Integrated...
AIEgen‐Based Photothermal Nanoparticles With Dual Antibacterial and Anti‐Inflammatory Activities for Enhanced Healing of Infected Diabetic Wounds
Researchers have engineered an aggregation‑induced emission luminogen (AIEgen) that converts near‑infrared light into heat, forming photothermal nanoparticles for diabetic wound therapy. The NIR‑activated particles efficiently kill multidrug‑resistant bacteria such as MRSA and carbapenem‑resistant Pseudomonas, while also disrupting biofilms and mitigating...
Engineered Biomimetic Nanorobots Orchestrate Targeted Nose‐to‐Brain Delivery to Resolve Neuron‐Glia Entanglement Against Parkinson's Disease
Researchers have engineered a biomimetic nanorobot (hPH‑RNPEC) that can be administered intranasally to deliver a combined payload of endogenous miRNAs and curcumin directly to the brain. The platform uses Pueraria lobata‑derived exosomes cloaked in neutrophil‑like membranes, a rabies virus glycoprotein...
Programmable G‐Quadruplex@DNA Nano‐Highway Network Platform Enables One‐Pot Electrochemical Detection of Exosomes for Breast Cancer Lymph Node Metastasis Evaluation
Researchers have created a rapid, one-pot electrochemical sensor for breast‑cancer‑derived exosomes. The device leverages an aptamer‑triggered hybridization chain reaction combined with a streptavidin‑biotin cross‑link to assemble a G‑quadruplex‑DNA nano‑highway network at room temperature. Binding of the vimentin aptamer disassembles the...
Renovating Neural Networks With Viral‐Mediated Gene Transfer From A Tissue Contacting Matrix Mimic
Researchers engineered a self‑assembling peptide hydrogel (Fmoc‑DDIKVAV) to encapsulate adeno‑associated virus delivering brain‑derived neurotrophic factor (AAV‑BDNF). In a mouse Huntington's disease model, the hydrogel‑mediated delivery achieved markedly higher BDNF expression and neuroprotection in the striatum than direct AAV injection. The...